Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

An Early Exploratory Clinical Trial to Evaluate CG-BM1 Allogeneic Human Bone Marrow Mesenchymal Stem Cell Injection in the Treatment of Sarcopenia

Authors not listed

GuangZhou Cellgenes Biotechnology Co., Ltd. · 2026

Abstract

1. To evaluate the safety and tolerability of CG-BM1 for the treatment of patients with Sarcopenia. 2. To observe the preliminary effectiveness of CG-BM1 in treating Sarcopenia patients.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-04 MST

Cite this

APA
Anonymous. (2026). An Early Exploratory Clinical Trial to Evaluate CG-BM1 Allogeneic Human Bone Marrow Mesenchymal Stem Cell Injection in the Treatment of Sarcopenia. <em>GuangZhou Cellgenes Biotechnology Co., Ltd.</em>. https://clinicaltrials.gov/study/NCT07865676
Vancouver
Anonymous. An Early Exploratory Clinical Trial to Evaluate CG-BM1 Allogeneic Human Bone Marrow Mesenchymal Stem Cell Injection in the Treatment of Sarcopenia. GuangZhou Cellgenes Biotechnology Co., Ltd.. 2026.
BibTeX
@misc{anon2026AnEarl, title = {An Early Exploratory Clinical Trial to Evaluate CG-BM1 Allogeneic Human Bone Marrow Mesenchymal Stem Cell Injection in the Treatment of Sarcopenia}, author = {Anonymous}, journal = {GuangZhou Cellgenes Biotechnology Co., Ltd.}, year = {2026}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings